tbuckley/cabot-search huggingface dataset:
FRI0260 The Assessment of Disease Activity in Takayasu Arteritis; Six Years Experience from a Single Center: Table 1.
Authors: S. Gulsaran, P. Cetin, D. Solmaz, S. Akar, H. Yarkan, A. Gulcu, Y. Goktay, M. Birlik, N. Akkoc, F. Onen
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Takayasu Arteritis (TA) is a chronic vasculitis of the aorta and its major branches affecting commonly young females. The current clinical and laboratory parameters of TA are insufficient for proper assessment of disease activity. <h3>Objectives</h3> The aim of this study is to analyze the activity parameters that affect the physicians9 global opinion (PGO) in TA. <h3>Methods</h3> The demographic and clinical data of patients with TA who were followed in the Rheumatology clinic at Dokuz Eylul University were retrospectively evaluated. Disease activity was assessed using various tools, including Kerr9s criteria, disease extent index-Takayasu (DEI.Tak), the Indian Takayasu Activity Score (ITAS2010), PGO, radiological activity parameters, and acute-phase reactants at every 3-6 months.According to the TA follow-up protocol of the Rheumatology and Radiology Board of our hospital, the patients were followed using 3-6 monthly B-mode/Doppler US examinations and 6-12 monthly magnetic resonance imaging (MRI) examinations with MRA.The agreement between disease activity parameters were assessed by kappa coefficient and Spearman rank correlation. <h3>Results</h3> In total, 52 patients (48 females; mean age: 46.8±13.2 years) who fulfilled the American College of Rheumatology (ACR) criteria for TA were enrolled in this study. Their mean disease duration was 9.7±7.6 years and mean follow-up duration was 6.4±2.9 years. 33 (63.5%) patients had type 5 TA and 13 (25%) had type 1 TA. 40 (76.9%) patients were categorized as having active disease in their first visits according to PGO. In the last visit, 31 (59.6%) patients had inactive disease, 19 (36.5%) had persistent disease and 2 (%3.9) had active disease. All the patients used the long-term glucocorticoid therapy and DMARD/immunosuppressive drugs. Six (%11.5) of them were on the treatment with biologics. Five (9.6%) patients underwent vascular surgery and 35 (67.3%) were performed endovascular repair for arterial stenosis. In total, 360 visits of 52 patients were evaluated. PGO was that the disease was inactive in the 181 visits, persistan in the 99 visits and active in the 80 visits. To obtain more clear results, visits with persistan disease were excluded and final evaluation included the 261 visits of 52 TA patients. Correlations of the clinical, laboratory and radiological activity parameters with each other and PGO were shown in Table 1. <h3>Conclusions</h3> The results of this study suggests that imaging had a significant impact on physician9s decision regarding disease activity in TA. Although disease activity scores including NIH, DEI-Tak and ITAS2010 were well correlated with each other, there was a poor agreement between CRP and all the other activity parameters. <h3>Disclosure of Interest</h3> None declared
SAT0556 Methotrexate Efficacy in Early Psoriatic Arthritis – Open Label Data from the Ticopa Study
Authors: L.C. Coates, P.S. Helliwell
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Methotrexate (MTX) is a common first line DMARD in psoriatic arthritis (PsA) but until recently no RCTs evaluating its efficacy in PsA were available. The MIPA trial found no significant difference in arthritis outcomes at 6 months but was criticised as the target dose was only 15mg. <h3>Objectives</h3> The aim of this analysis was to investigate clinical outcomes in patients with early PsA treated with MTX in the TICOPA study. <h3>Methods</h3> Within the Tight Control of Psoriatic Arthritis, patients (in either arm) could be treated with methotrexate. All patients in the tight control arm received MTX as first line monotherapy for the first 12 weeks while patients in the standard care arm the majority of the patients in the standard care arm also received MTX. Clinical outcomes were recorded at the 12 week visit including joint counts, PASI, NAPSI, enthesitis and dactylitis measures. <h3>Results</h3> Of the 206 patients enrolled in TICOPA, 188 received oral methotrexate in the first 12 weeks of the trial. Of these, 175 patients reached a dose of at least 15mg by 12 weeks, with 122 reaching a dose of at least 20mg and 86 reaching the top dose of 25mg. The proportions of patients achieving the ACR outcomes at 12 weeks were ACR20 40.8%, ACR50 18.8% and ACR70 8.6% with 22.4% achieving minimal disease activity (MDA). Improvements were also seen in PASI scores with 27.2% reaching a PASI75. For those with enthesitis at baseline (n=148) the median change in enthesitis score was 0 (IQ range -1, 0 for LEI and IMPACT, -2, 1 for MASES). For those with baseline dactylitis (n=59), there was a median change in LDI scores of -59.7 (-157.4, -26.4). 117 patients had nail involvement and these patients showed a median change in mNAPSI score of -2 (IQ range -8, 0) with changes more commonly in the nail bed due to the short follow up time. Slightly higher proportions of patients receiving 180mg MTX or more over the 12 week period (equivalent to an average of 15mg per week) achieved ACR20, 50 and PASI 75 but the numbers were small so this did not reach significance. <h3>Conclusions</h3> Despite this data being open-label, it does show improvements in multiple clinical outcomes associated with MTX use in PsA. The proportion reaching ACR20 is slightly higher than that in MIPA (41 vs 34%) but no comparative data are available for the other outcomes. There is a suggestion of better responses with doses above 15mg per week but the dose-response is harder to assess in such a study where confounding exists as patients doing well may be left on lower doses. <h3>Disclosure of Interest</h3> L. Coates: None declared, P. Helliwell Grant/research support from: Pfizer, Consultant for: Pfizer
Effects of the Monoamine Oxidase Inhibitor, Tranylcypromine, on Induction of HL60 Cell Differentiation by Hexamethylene Bisacetamide and <i>N</i>-Acetyl-1,6-Diaminohexane
Authors: S W Snyder, M J Egorin, E G Zuhowski, E C Schimpff, P S Callery
Journal: Cancer Communications (1990)

Hexamethylene bisacetamide (HMBA) is converted by successive deacetylation and oxidation reactions to four major metabolites; in vitro, the initial deacetylated metabolite, N-acetyl-1,6-diaminohexane (NAD-AH), is more potent than HMBA (Synder, S.W.; Egorin, M.J.; Geelhaar, L.A.; Hamburger, A.W.; Callery, P.S. Cancer Res. 48:3613-3616; 1988). We propose that monoamine oxidase (MAO) catalyzed metabolism of NADAH to 6-acetamidohexanoic acid (AcHA) is an inactivation pathway and, therefore, investigated whether blocking such metabolism with the MAO inhibitor, tranylcypromine, would potentiate induction of cell differentiation by HMBA and NADAH. Tranylcypromine, at concentrations up to 30 micrograms/mL, did not inhibit HL60 cell growth and did not induce differentiation of HL60 cells. Tranylcypromine did, however, produce concentration-dependent enhancement of HMBA- and NADAH-induced differentiation. In contrast, 30 micrograms/mL of tranylcypromine did not effect the ability of dimethylsulfoxide, at concentrations between 0.25% and 1.25%, to induce differentiation of HL60 cells. Tranylcypromine, at 30 micrograms/mL, did not change cellular concentrations of HMBA or NADAH but did reduce intracellular concentrations of AcHA, consistent with inhibition of MAO catalyzed conversion of NADAH to AcHA. These results support the hypothesis that MAO catalyzed metabolism of NADH to AcHA is an inactivation pathway and may provide the basis for a clinical trail in which HMBA metabolism is modulated with concurrent tranylcypromine therapy.
Best practices in ranking communicable disease threats: a literature review, 2015
Authors: Eleanor Charlotte O’Brien, Rachel Taft, Katie Geary, Massimo Ciotti, Jonathan E Suk
Journal: Eurosurveillance (2016)

The threat of serious, cross-border communicable disease outbreaks in Europe poses a significant challenge to public health and emergency preparedness because the relative likelihood of these threats and the pathogens involved are constantly shifting in response to a range of changing disease drivers. To inform strategic planning by enabling effective resource allocation to manage the consequences of communicable disease outbreaks, it is useful to be able to rank and prioritise pathogens. This paper reports on a literature review which identifies and evaluates the range of methods used for risk ranking. Searches were performed across biomedical and grey literature databases, supplemented by reference harvesting and citation tracking. Studies were selected using transparent inclusion criteria and underwent quality appraisal using a bespoke checklist based on the AGREE II criteria. Seventeen studies were included in the review, covering five methodologies. A narrative analysis of the selected studies suggests that no single methodology was superior. However, many of the methods shared common components, around which a 'best-practice' framework was formulated. This approach is intended to help inform decision makers' choice of an appropriate risk-ranking study design.
Pott’s Disease
Authors: HÜSEYİN ÇAKSEN, KAZIM ÜZÜM, AHMET TUTUS
Journal: Clinical Nuclear Medicine (2001)

A 15-year-old boy was hospitalized with a 1-month history lumbago and fever. His family history was noncontributory for tuberculosis, and the findings of the physical examination were normal. The sedimentation rate and C-reactive protein level were 55 mm/hour and 48 mg/l, respectively. The result of a purified protein derivative test was 11 x 10 mm. Results of other tests, including rheumatologic studies, serum agglutination for brucellosis, chest radiography, abdominal ultrasonography, and myelography, were normal. The bone biopsy revealed chronic active inflammation. Mycobacterium tuberculosis was not cultured from clinical specimens. However, the patient's symptoms improved after antituberculosis drugs were begun.
Pseudohepatic Cavernous Hemangioma Resulting from a Prominent Left Portal Vein of a Portal Systemic Shunt Collateral on Tc-99m SPECT Red Blood Cell Scintigraphy
Authors: DAN VU, FELIX WANG, THERON BROWN
Journal: Clinical Nuclear Medicine (2001)

From the Department of Radiological Sciences, University of California, Irvine Medical Center, Orange, California Received for publication July 10, 2000. Accepted July 26, 2000. Reprint requests: Felix Wang, M.D., Department of Radiological Sciences, University of California, Irvine Medical Center, 101 The City Drive, Orange, California 92868.
Frequent occurrence of therapeutically reversible CMV-associated encephalopathy during radiotherapy of the brain
Authors: Nicole L. Goerig, Benjamin Frey, Klaus Korn, Bernhard Fleckenstein, Klaus Überla, Manuel A. Schmidt, Arnd Dörfler, Tobias Engelhorn, Ilker Eyüpoglu, Paul F. Rühle, Florian Putz, Sabine Semrau, Udo S. Gaipl, Rainer Fietkau
Journal: Neuro-Oncology (2016)

Neurological decline during radio(chemo)therapy of the brain is often attributed to disease progression or side effects of radiotherapy. Diagnosis of opportunistic neurotropic infections such as cytomegalovirus (CMV) infections is uncommon, even though high-grade gliomas and some brain metastases are known to contain CMV particles. We prospectively examined the frequency of CMV encephalopathy during radiotherapy of the brain. Fifty patients requiring whole-brain radiotherapy for brain metastases (n = 27) or local radio(chemo)therapy of the brain for high-grade gliomas (n = 23) were observed in the prospective observational GLIO-CMV-01 study. MRIs and blood samples were obtained before, halfway through, and at the end of radiotherapy. MRIs were screened for disease progression or increased intracranial pressure. Blood was tested for anti-CMV immunoglobulin (Ig)M, anti-CMV IgG, and CMV DNA. Thirty-two of 50 (64%) patients were positive for anti-CMV IgG before radio(chemo)therapy. Fifteen of those 32 (48%) developed viremia during or up to 28 days after treatment. Thirteen of those 15 (87%) required treatment for CMV-associated encephalopathy. MRIs were negative for disease progression, edema, or bleeding. None of the patients negative for anti-CMV IgG developed viremia, suggesting a reactivation rather than a primary infection. In the group at risk consisting of anti-CMV IgG+ patients, age >65 (P = .004) and the amount of dexamethasone taken during radio(chemo)therapy (P = .004) were associated with an increased risk for CMV-associated encephalopathy. One hundred and fifty days after the start of radio(chemo)therapy, survival was 74% (14/19) (no encephalopathy) versus 54% (7/13) (encephalopathy) (odds ratio, 0.42; 95% CI, 0.03–1.86; P = .25). CMV reactivation frequently causes encephalopathy during radio(chemo)therapy of the brain. The unexpected high incidence of this infection makes it highly clinically relevant for every treating physician.
Massachusetts Medical Society
Authors: John Figgis Jewett
Journal: New England Journal of Medicine (1972)

COMMITTEE ON MATERNAL WELFAREFatal Laceration from Normal BirthSpontaneous pneumothorax during the first trimester of a first pregnancy was easily corrected by thoracostomy. Otherwise normal, the 23-year-old patient was delivered of a 3570-g infant 18 days after term and nine hours after labor began. A right mediolateral episiotomy was needed, but no forceps, and the third stage of 10 minutes ended uneventfully at 1:22 p.m. No lacerations were detected, the episiotomy was repaired, and the patient recovered from anesthesia in about 30 minutes.One hour post partum large blood clots were passed, oxytocin (Pitocin) was started intravenously, blood was . . .
Autoradiographic Analysis of Cell Proliferation in Spontaneous Breast Cancer of C3H Mouse. I. Typical Cell Cycle and Timing of DNA Synthesis&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Mortimer L. Mendelsohn, F. Curtis Dohan, Jr., Hugh A. Moore, Jr.
Journal: JNCI Journal of the National Cancer Institute (1960)

Primary breast tumors of the C3H mouse and autotransplants of these tumors have been labeled in situ by intraperitoneal or intravenous injection of tritiated thymidine. From the frequency of labeled mitotic cells at various times after injection a typical cell cycle has been formulated. This cycle is completed in 1 to 3½ days. The synthesis of deoxyribonucleic acid (DNA) occurs in 9 to 13 hours, and there is a 1- to 4-hour period between the completion of DNA synthesis and the onset of mitosis. In many tumors this typical cycle applies to nearly all dividing cells. A comparison between different tumors and between these tumors and other cell systems indicates that variation in intermitotic time is primarily related to the duration of the presynthetic period. The growth rate of these tumors is limited by factors other than the rate at which the cells synthesize DNA.
Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science
Authors: Paul M. Hassoun, Steven D. Nathan
Journal: European Respiratory Journal (2016)

The last few years have seen the development and approval of two drugs, pirfenidone and nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF) [1–3]. Both agents have been shown to slow the loss of lung function and, therefore, target progressive fibrosis. While the availability of these agents has been a welcome breakthrough, it is well recognised that they both have limited effect, and there remain many unmet needs [4] and a dire necessity for additional therapies [4, 5]. Aside from the fibrotic component of the disease, another pathophysiological consequence that may supervene in IPF patients is pulmonary hypertension (PH) [6]. PH complicating the course of patients with pulmonary fibrosis has a strong association with functional impairment and worse outcomes. The likelihood of developing PH increases over time and, in the terminal phases of the disease, most patients have developed an element of PH [7]. Therefore, in patients with more advanced disease who have established PH or are at high risk of developing PH, pulmonary vasoactive agents might represent a viable therapeutic option. Targeting PH in IPF makes intuitive sense, but the challenges lie in not only choosing the most appropriate patient population but also the right medication or class of medications. Sildenafil may be of benefit in IPF with out-of-proportion PH and could be a step toward effective multimodal therapy <http://ow.ly/YYYap>
OP0191 Prophylaxis for the Prevention of Obstetric Complications in Asymptomatic Women with Antiphospholipid Antibodies
Authors: O. Amengual, D. Fujita, E. Otta, L. Carmona, O. Kenji, M. Sugiura-Ogasawara, A. Murashima, T. Atsumi
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The occurrence of recurrent thrombotic events and/or of obstetric complications in association with the persitence of antiphospholipid antibodies (aPL) defines the antiphospholipid syndrome (APS). Positive aPL can be recognized through the screening of otherwise asymptomatic pregnancies, however, the effect of aPL in the pregnancy outcomes of asymptomatic aPL carriers is uncertain. <h3>Objectives</h3> To evaluate whether primary prophylaxis would be beneficial to prevent obstetric complications in asymptomatic women positive for aPL who have no history of clinical manifestations of APS. <h3>Methods</h3> We performed a systematic review of the literature. Studies evaluating the effect of prophylactic treatment vs. no treatment in asymptomatic pregnant aPL carriers were identified in an electronic database search. The literature search was performed in the major databases: Medline from 1950 via PubMed, Embase, and the Cochrane Central Register of Controlled Trials. Conference abstracts of six major international conferences were searched from January 2012 to July 2014 on their official webpages. Design, population, and outcome homogeneity of studies were assessed and meta-analysed. Risk of bias was assessed through an ad hoc checklist. The pooled Mantel-Haenszel relative risk (RR) and 95% confidence interval (CI) of specific pregnancy outcomes were obtained using random effects models. Heterogeneity was measured with the I<sup>2</sup> statistic. All analyses were conducted in Review Manager 5.3. <h3>Results</h3> Data from five studies with moderate to low risk of bias involving 154 pregnancies were included and three studies were meta-analysed. The RR of live birth rates, preterm birth, low birth weight and overall pregnancy complications in treated vs. un-treated pregnancies were 1.14 [0.18-7.31]; 1.71 [0.32 - 8.98]; 0.98; [0.07 -13.54] and 2.15 [0.63-7.33], respectively. Results from the meta-analysis could not prove that treatment with aspirin was superior to placebo to prevent pregnancy complications in asymptomatic aPL carriers. <h3>Conclusion</h3> This systematic review did not find evidence of the superiority of prophylactic treatment with aspirin compared to placebo or to usual care for preventing unfavourable obstetric outcomes in otherwise healthy women with aPL during the first pregnancy. <h3>Disclosure of Interest</h3> O. Amengual: None declared, D. Fujita: None declared, E. Otta: None declared, L. Carmona: None declared, O. Kenji: None declared, M. Sugiura-Ogasawara: None declared, A. Murashima: None declared, T. Atsumi Grant/research support from: Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Bristol-Myers Squibb Co., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd. and Mitsubishi Tanabe Pharma Co., Speakers bureau: Astellas Pharma Inc. and Mitsubishi Tanabe Pharma Co.
Recent trends in Chlamydia trachomatis in the United Kingdom and the potential for national screening
Authors: Jeanne Pimenta, K. A. Fenton
Journal: Eurosurveillance (2001)

A pilot study has been carried up in the United Kingdom to assess the feasibility of a national screening programme of genital chlamydial infections. The preliminary results show a high acceptance rate (70% of the candidates) and a significant coverage of the target population (40% over a six months period). Several other studies are ongoing in order to specify the more appropriate screening processes and partner notification strategies, as well as the cost effectiveness of a national programme.
Syphilis Screening Recommendation in Nonpregnant Adults and Adolescents
Authors: Katherine K. Hsu, Gale R. Burstein
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Global absence of pulmonary perfusion in a hypoplastic lung with pulmonary artery agenesis associated with immunoglobulin a deficit.
Authors: R Martínez-Lázaro, A Cortés-Blanco, J Banzo
Journal: Clinical Nuclear Medicine (2001)

MARTÍNEZ-LÁZARO, RAUL M.D., Ph.D.*; CORTÉS-BLANCO, ANABEL M.D., Ph.D.*; BANZO, JAVIER M.D., Ph.D.† Author Information